ASX Announcement

29 November 2023

OncoSil onboards first patient in PANCOSIL Clinical Trial

Melbourne, Australia – 29 November 2023: OncoSil Medical Ltd (ASX: OSL) (OncoSil or the Company), a medical device company focused on localised treatments for patients with locally advanced pancreatic cancer (LAPC), announces;

The first patient has been treated in the PANCOSIL Investigator Initiated Clinical Trial on 28 November 2023. This study received ethics approval back in June 2023.

Key Highlights

- The first patient in the PANCOSIL Investigator Initiated Clinical Trial has been treated on 28 November 2023.
- This Trial is examining the safety and feasibility of the OncoSil™ device utilizing percutaneous application for patients with locally advanced pancreatic cancer.
- In all, 20 patients will be treated with the OncoSil™ device by percutaneous application over the course of the Trial.
- The aim of the trial is to assess the safety of percutaneous application of the OncoSil device which allows for expansion of the user base.

Another clinical trial using the OncoSil™ device

The first patient has been treated in PANCOSIL Investigator Initiated Clinical Trial on 28 November 2023 in Amsterdam. This comes in the wake of ethics approval for the trial being granted in June 2023 (see OncoSil Medical ASX announcement, dated 5 June 2023).

PANCOSIL is an Investigator Initiated Clinical Trial looking at the safety and feasibility of CT-guided percutaneous radionuclide therapy with the OncoSil™ device in patients with non-progressive locally advanced pancreatic cancer.

In all, 20 patients will be treated with the OncoSil™ device by percutaneous application over the course of the trial. This will, in turn, expand the available users who can deliver the OncoSil™ device.

Most of the funding contribution by OncoSil has already occurred in previous quarters.

ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL
Suite 1, Level 3, 62 Lygon Street, Carlton South, VIC 3053 AUSTRALIA
TELEPHONE +61 2 9223 3344 FACSIMILE +61 2 9252 3988
WEB www.oncosil.com

Professor Doctor Martijn Meijerink said: "I am very excited that today we have been able to treat the first patient with OncoSil™ through a CT-guided percutaneous implantation procedure. This novel means of implantation of the OncoSil™ device has a number of potential advantages, such as the ability to more precisely place the radioactive microparticles within the pancreatic tumour in a simpler procedure, which can be performed by interventional radiologists many of whom are used to working with radionuclide therapies in the treatment of various malignant diseases."

The Lead Investigator at Amsterdam UMC, Professor Marc Besselink said: "Today we set the first step in developing a more flexible approach to the OncoSil™ treatment by implanting the first patient using a percutaneous CT-guided approach. Eventually, we aim to give caregivers more flexibility to treat their patients with Locally Advanced Pancreatic Cancer with OncoSil™ as they will have the ability to select the route of administration of the device based on the tumour location, patient preference and the availability of different specialists within the multidisciplinary treatment team."

OncoSil Medical CEO & Managing Director Nigel Lange said: "We are excited by news that the first patient has been treated in the PANCOSIL study. The recruitment of patients to this study represents another significant milestone in our efforts to commercialise the OncoSil™ device. We expect the results of the study will help us to develop an alternative technique for OncoSil™ implantation and provide flexibility for users. This and other outcomes emerging from the PANCOSIL study will open the way for an increased number of medical professionals to deliver the OncoSil™ device to patients with locally advanced pancreatic cancer."

Authorisation & Additional Information

This announcement was authorised by the Managing Director of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 16096424981	Mr. Christian Dal Cin The CFO Solution CFO & Company Secretary E: christian@thecfo.com.au T: +61 3 9824 5254	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699

About OncoSil

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival[1].

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

Forward Looking Statements

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil Medical is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.